Regulatory/GMP Compliance, Emerging Markets

The campaign supports pharmaceutical growth in India and serves to highlight the value proposition that Indian pharmaceuticals present.

Is there potential for growth in Brazil's phytotherapic drug market?

An established drug-manufacturing base with quality and safety issues, and patent protection and price capping concerns complicate efforts to do business in India.

How badly is Brazil's pharmaceutical market suffering from the global instability of emerging markets?

Biopharma companies should not overlook India's growing market.

How badly is Brazil's pharmaceutical market suffering from the global instability of emerging markets?

China's regulatory and compliance environment is set to change as the government declares a crackdown on bribery scandals.

In first official visit to India, FDA commissioner to discuss ongoing collaboration on drug programs.

Some recent high-profile cases of quality issues at Indian manufacturers have given reason to examine manufacturers more closely.

India has a name when it comes to generic drug development. According to a recent research on patent applications carried out by Withers & Rogers, innovation by Indian pharmaceutical companies has increased over the past few years; however, the quality did not match the standard seen in Europe.

Brazil is the first Latin American country to emerge as a global biopharmaceutical collaborator.

Siegfried Schmitt, principal consultant at PAREXEL, discusses the state of drug manufacturing in India.

Mylan and the Indian biopharmaceutical company Biocon receive approval for a biosimilar version of trastuzumab in India. Also, Mylan and Teva reach settlement on Copaxone in the EU.

New regulation offers patients in Brazil greater access to experimental drugs.

IBEF and Pharmexcil report the country?s plans for growth and its commitment to lowering the cost of medicines globally.

The pharmaceutical industry grows despite conflict in the Middle East.

Foreign companies zero in on Myanmar with the hope of securing a foothold in its pharmaceutical market.

Pharma eyes biologics production in Brazil as the government begins to recognize the potential of these drugs.

The last few weeks have seen the media swamped with stories about the rampant bribery clawing the pharmaceutical industry in China.

Industry players brace themselves to face challenges as India's new drug-pricing policy kicks in full gear.

The bio-pharmaceutical business outlook in South Korea remains positive.

Brazil offers opportunities and challenges for global pharmaceutical companies.

The Alliance for Fair Trade with India is seeking action to resolve discriminatory trade practices and improved protection of intellectual property rights.

A unique demographic and payer mix make ASEAN an increasingly attractive region.

The Taiwanese government engages in regulatory science in a move to boost its pharmaceutical sector.

Prior to price escalation of pharmaceutical products in Brazil, the country's regulatory authority released a study on price-cap control and its benefits in the past years.

Ruling has implications for intellectual property protection for innovator drugs in India.

Latin America's diverse growing market seeks regulatory harmonization.

Novartis loses an appeal in seeking patent protection in India for its anticancer drug.

The Thai government is ramping up efforts to promote and develop the biotechnology sector in a bid to enhance its global competitiveness.